📊 RGNX Key Takeaways
Is REGENXBIO Inc. (RGNX) a Good Investment?
RGNX exhibits severe financial distress with $90.1M net losses against $6.4M revenue and unsustainable -$77.4M free cash flow burn. With only $15.2M cash and $320.8M liabilities against $21.1M stockholders' equity, the company faces critical liquidity risk and requires immediate capital infusion to survive. Without demonstrable revenue growth or near-term commercialization success, fundamental viability is highly questionable.
Fundamentals are weak: losses are large and persistent with operating and net margins deeply negative, while revenue growth is flat. Although the company carries no debt and maintains a solid current ratio, cash on hand appears insufficient relative to the heavy operating cash burn, implying near‑term financing risk. Without clear improvement in revenue traction or cost discipline, the risk/reward skews unfavorably.
REGENXBIO Inc. Key Strengths (RGNX)
- Current ratio of 2.62x provides short-term liquidity buffer
- No long-term debt burden reducing servicing obligations
- Net loss improved 14.6% YoY indicating marginal operational progress
- Debt-free balance sheet (0.00x D/E)
- Solid liquidity (2.38x current and quick ratios)
- Low capital intensity (minimal capex)
RGNX Stock Risks: REGENXBIO Inc. Investment Risks
- Catastrophic burn rate of -$77.4M free cash flow against $15.2M cash reserves (~2 months runway)
- Stockholders' equity depleted to $21.1M with $320.8M total liabilities indicating structural insolvency risk
- Zero revenue growth (0.0% YoY) with revenue of only $6.4M inadequate to support R&D stage company
- Negative equity returns (-427.1% ROE) destroying shareholder value at unsustainable rate
- Minimal insider buying activity (2 Form 4s/90 days) suggests low confidence from management
- Sustained large operating losses (-94.6% operating margin)
- Heavy negative free cash flow versus limited cash ($34.5M)
- Flat revenue (+0.0% YoY) with uncertain visibility
Key Metrics to Watch
- Cash runway and next funding event timeline
- Pipeline milestone achievements and clinical trial progression
- Monthly operating burn rate trend and cash position changes
- Revenue growth inflection or product commercialization progress
- Operating cash flow (burn rate)
- Revenue growth YoY
REGENXBIO Inc. (RGNX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.62x current ratio provides a solid financial cushion.
RGNX Profit Margin, ROE & Profitability Analysis
RGNX vs Healthcare Sector: How REGENXBIO Inc. Compares
How REGENXBIO Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is REGENXBIO Inc. Stock Overvalued? RGNX Valuation Analysis 2026
Based on fundamental analysis, REGENXBIO Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
REGENXBIO Inc. Balance Sheet: RGNX Debt, Cash & Liquidity
RGNX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: REGENXBIO Inc.'s revenue has declined by 64% over the 5-year period, indicating business contraction. The most recent EPS of $-4.59 indicates the company is currently unprofitable.
RGNX Revenue Growth, EPS Growth & YoY Performance
RGNX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $6.4M | $6.1M | $0.12 |
| Q3 2025 | $24.2M | -$59.6M | $-1.17 |
| Q2 2025 | $21.4M | -$53.0M | $-1.05 |
| Q1 2025 | $15.6M | $6.1M | $0.12 |
| Q3 2024 | $24.2M | -$59.6M | $-1.17 |
| Q2 2024 | $20.0M | -$53.0M | $-1.05 |
| Q1 2024 | $15.6M | -$63.3M | $-1.38 |
| Q3 2023 | $26.5M | -$61.9M | $-1.41 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
REGENXBIO Inc. Dividends, Buybacks & Capital Allocation
RGNX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for REGENXBIO Inc. (CIK: 0001590877)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RGNX
What is the AI rating for RGNX?
REGENXBIO Inc. (RGNX) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RGNX's key strengths?
Claude: Current ratio of 2.62x provides short-term liquidity buffer. No long-term debt burden reducing servicing obligations. ChatGPT: Debt-free balance sheet (0.00x D/E). Solid liquidity (2.38x current and quick ratios).
What are the risks of investing in RGNX?
Claude: Catastrophic burn rate of -$77.4M free cash flow against $15.2M cash reserves (~2 months runway). Stockholders' equity depleted to $21.1M with $320.8M total liabilities indicating structural insolvency risk. ChatGPT: Sustained large operating losses (-94.6% operating margin). Heavy negative free cash flow versus limited cash ($34.5M).
What is RGNX's revenue and growth?
REGENXBIO Inc. reported revenue of $6.4M.
Does RGNX pay dividends?
REGENXBIO Inc. does not currently pay dividends.
Where can I find RGNX SEC filings?
Official SEC filings for REGENXBIO Inc. (CIK: 0001590877) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RGNX's EPS?
REGENXBIO Inc. has a diluted EPS of $-1.72.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is RGNX's fundamental grade?
Based on our AI fundamental analysis in June 2026, REGENXBIO Inc. has a D grade with 86% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is RGNX stock overvalued or undervalued?
Valuation metrics for RGNX: ROE of -427.1% (sector avg: 15%), net margin of -1,408.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is RGNX's AI grade for 2026?
Our dual AI analysis gives REGENXBIO Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RGNX's free cash flow?
REGENXBIO Inc.'s operating cash flow is $-76.2M, with capital expenditures of $1.2M. FCF margin is -1,211.0%.
How does RGNX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,408.6% (avg: 12%), ROE -427.1% (avg: 15%), current ratio 2.62 (avg: 2).